Table 3. Baseline characteristics for MACE analysis.
| Characteristics | Total (n = 245) | Non-MACE (n = 200) | MACE (n = 45) | P-value |
| Data are presented as means ± SD or n (%). *Presented as median (interquartile range). MACE: major adverse cardiovascular event. | ||||
| Age, yrs | 65.91 ± 11.66 | 65.03 ± 11.34 | 69.82 ± 12.41 | 0.021 |
| Male | 146 (59.60%) | 120 (60.00%) | 26 (57.78%) | 0.784 |
| Body mass index, kg/m2 | 25.47 (23.99−26.55)* | 25.56 (24.23−26.57)* | 24.80 (22.94−26.47)* | 0.076 |
| Smoker | 124 (50.60%) | 104 (52.00%) | 20 (44.44%) | 0.360 |
| Hypertension | 162 (66.10%) | 135 (67.50%) | 27 (60.00%) | 0.337 |
| Diabetes mellitus | 72 (29.40%) | 59 (29.50%) | 13 (28.90%) | 0.935 |
| Left ventricular ejection fraction, % | 51.00 (44.00−58.00)* | 51.00 (44.00−58.00)* | 49.00 (40.00−56.50)* | 0.168 |
| Disease types | 0.893 | |||
| ST-segment elevation myocardial infarction | 187 (76.30%) | 153 (76.50%) | 34 (75.60%) | |
| Non-ST-segment elevation myocardial infarction | 58 (23.70%) | 47 (23.50%) | 11 (24.40%) | |
| Laboratory examination | ||||
| White blood cells, × 109/L | 9.05 (6.96−11.59)* | 9.06 (6.98−11.54)* | 8.25 (6.73−11.84)* | 0.996 |
| Neutrophils, × 109/L | 6.65 (4.51−9.24)* | 6.67 (4.55−8.95)* | 6.35 (4.30−9.65)* | 0.811 |
| Platelets, × 109/L | 206.00 (177.00−252.00)* | 209.00 (179.00−255.00)* | 196.00 (157.00−236.00)* | 0.065 |
| Mean platelet volume, fl | 10.50 (10.00−11.20)* | 10.50 (9.90−11.10)* | 10.80 (10.10−11.40)* | 0.217 |
| Platelet distribution width, fl | 12.20 (11.00−13.50)* | 12.05 (10.90−13.40)* | 12.90 (11.40−14.30)* | 0.076 |
| Platelet hematocrit, % | 0.22 (0.19−0.26)* | 0.22 (0.19−0.27)* | 0.22 (0.17−0.25)* | 0.176 |
| Creatine kinase, U/L | 528.00 (108.50−1784.00)* | 515.00 (115.25−1735.00)* | 549.00 (88.50−2039.00)* | 0.865 |
| Creatine kinase-MB, U/L | 55.00 (18.00−174.00)* | 54.50 (18.00−170.25)* | 64.00 (18.50−182.00)* | 0.843 |
| High-sensitivity C-reactive protein, mg/L | 4.53 (1.63−14.93)* | 4.05 (1.52−10.65)* | 8.81 (2.34−39.06)* | 0.008 |
| Lipoprotein(a), nmol/L | 35.70 (12.70−83.40)* | 35.65 (12.73−85.30)* | 35.70 (12.65−80.90)* | 0.812 |
| Total cholesterol, mmol/L | 4.42 (3.77−5.14)* | 4.42 (3.82−5.14)* | 4.19 (3.31−5.02)* | 0.163 |
| Triglycerides, mmol/L | 1.42 (1.08−2.01)* | 1.44 (1.09−2.05)* | 1.30 (0.99−1.81)* | 0.186 |
| Apolipoprotein A, g/L | 1.18 (1.03−1.35)* | 1.19 (1.04−1.35)* | 1.18 (1.02−1.34)* | 0.326 |
| Apolipoprotein B, g/L | 1.03 (0.84−1.25)* | 1.07 (0.85−1.26)* | 0.99 (0.76−1.21)* | 0.136 |
| High-density lipoprotein, mmol/L | 1.07 (0.85−1.29)* | 1.04 (0.85−1.30)* | 1.09 (0.89−1.24)* | 0.709 |
| Low-density lipoprotein, mmol/L | 2.94 (2.22−3.67)* | 2.98 (2.24−3.68)* | 2.81 (2.06−3.64)* | 0.283 |
| TroponinT, ng/mL | 1.48 (0.08−5.67)* | 1.34 (0.08−5.60)* | 2.19 (0.15−7.93)* | 0.390 |
| Brain natriuretic peptide, pg/mL | 833.70 (232.50−2477.00)* | 708.90 (198.20−1938.75)* | 1461.00 (555.90−4662.00)* | 0.001 |
| Interventional therapy | ||||
| Door-to-balloon time, min | 76.00 (56.50−128.50)* | 74.50 (55.00−121.00)* | 81.00 (59.50−190.50)* | 0.346 |
| SYNTAX score | 33.50 (23.50−37.00)* | 33.00 (24.00−36.50)* | 34.00 (20.50−40.00)* | 0.160 |
| Target vessel | 0.893 | |||
| Left main artery | 7 (2.85%) | 6 (3.00%) | 1 (2.22%) | |
| Left anterior descending artery | 104 (42.45%) | 83 (41.50%) | 21 (46.67%) | |
| Left circumflex artery | 36 (14.70%) | 29 (14.50%) | 7 (15.56%) | |
| Right coronary artery | 98 (40.00%) | 82 (41.00%) | 16 (35.55%) | |
| Postoperative medication | ||||
| Aspirin | 245 (100%) | 200 (100%) | 45 (100%) | 1.000 |
| P2Y12 inhibitor | 243 (99.20%) | 199 (99.50%) | 44 (97.80%) | 0.334 |
| Angiotensin-converting enzyme inhibitors/
Angiotensin II receptor blockers |
209 (85.30%) | 173 (86.50%) | 36 (80.00%) | 0.266 |
| Statins | 245 (100%) | 200 (100%) | 45 (100%) | 1.000 |
| Beta-blocker | 223 (91.00%) | 182 (91.00%) | 41 (91.10%) | 0.981 |
| Lactobacillus | 7.09 (3.97−10.01)* | 7.77 (4.63−10.59)* | 4.55 (3.16−6.80)* | < 0.001 |